Rescue of Alzheimer's memory deficit achieved by reducing 'excessive inhibition'

June 13, 2014 by Barbara K. Kennedy
A new drug target to fight Alzheimer's disease has been discovered by a research team led by Gong Chen, a Professor of Biology and the Verne M. Willaman Chair in Life Sciences at Penn State University. The discovery also has potential for development as a novel diagnostic tool for Alzheimer's disease, which is the most common form of dementia and one for which no cure has yet been found. This image is a microscopic view showing high concentrations of the GABA neurotransmitter (red) in the reactive astrocytes (green) in a human brain with Alzheimer's disease. Credit: Gong Chen lab, Penn State University

A new drug target to fight Alzheimer's disease has been discovered by a research team led by Gong Chen, a Professor of Biology and the Verne M. Willaman Chair in Life Sciences at Penn State University. The discovery also has potential for development as a novel diagnostic tool for Alzheimer's disease, which is the most common form of dementia and one for which no cure has yet been found. A scientific paper describing the discovery will be published in Nature Communications on 13 June 2014.

Chen's research was motivated by the recent failure in of once-promising Alzheimer's drugs being developed by large pharmaceutical companies. "Billions of dollars were invested in years of research leading up to the clinical trials of those Alzheimer's drugs, but they failed the test after they unexpectedly worsened the patients' symptoms," Chen said. The research behind those drugs had targeted the long-recognized feature of Alzheimer's brains: the sticky buildup of the amyloid protein known as plaques, which can cause neurons in the brain to die. "The research of our lab and others now has focused on finding new drug targets and on developing new approaches for diagnosing and treating Alzheimer's disease," Chen explained.

"We recently discovered an abnormally high concentration of one inhibitory in the brains of deceased Alzheimer's patients," Chen said. He and his research team found the neurotransmitter, called GABA (gamma-aminobutyric acid), in deformed cells called "reactive astrocytes" in a structure in the core of the brain called the . This structure is the gateway to hippocampus, an area of the brain that is critical for learning and memory.

Chen's team found that the GABA neurotransmitter was drastically increased in the deformed versions of the normally large, star-shaped "astrocyte" cells which, in a healthy individual, surround and support individual neurons in the brain. "Our research shows that the excessively high concentration of the GABA neurotransmitter in these reactive astrocytes is a novel biomarker that we hope can be targeted in further research as a tool for the diagnosis and treatment of Alzheimer's disease," Chen said.

Chen's team developed new analysis methods to evaluate neurotransmitter concentrations in the brains of normal and genetically modified mouse models for Alzheimer's disease (AD mice). "Our studies of AD mice showed that the high concentration of the GABA neurotransmitter in the reactive astrocytes of the dentate gyrus correlates with the animals' poor performance on tests of learning and memory," Chen said. His lab also found that the high concentration of the GABA neurotransmitter in the reactive astrocytes is released through an astrocyte-specific GABA transporter, a novel drug target found in this study, to enhance GABA inhibition in the dentate gyrus. With too much inhibitory GABA neurotransmitter, the neurons in the dentate gyrus are not fired up like they normally would be when a healthy person is learning something new or remembering something already learned.

Importantly, Chen said, "After we inhibited the astrocytic GABA transporter to reduce GABA inhibition in the brains of the AD mice, we found that they showed better memory capability than the control AD mice. We are very excited and encouraged by this result, because it might explain why previous clinical trials failed by targeting alone. One possible explanation is that while amyloid plaques may be reduced by targeting amyloid proteins, the other downstream alterations triggered by amyloid deposits, such as the excessive GABA inhibition discovered in our study, cannot be corrected by targeting amyloid proteins alone. Our studies suggest that reducing the excessive GABA inhibition to the neurons in the brain's dentate gyrus may lead to a novel therapy for Alzheimer's disease. An ultimate successful therapy may be a cocktail of compounds acting on several drug targets simultaneously."

Explore further: Fruitfly study: Epilepsy drug target implications for sleep disruption in brain disorders

Related Stories

Fruitfly study: Epilepsy drug target implications for sleep disruption in brain disorders

April 1, 2014
A new study in a mutant fruitfly called sleepless (sss) confirmed that the enzyme GABA transaminase, which is the target of some epilepsy drugs, contributes to sleep loss. The findings, published online in Molecular Psychiatry, ...

Compound reverses symptoms of Alzheimer's disease in mice, research shows

May 20, 2014
A molecular compound developed by Saint Louis University scientists restored learning, memory and appropriate behavior in a mouse model of Alzheimer's disease, according to findings in the May issue of the Journal of Alzheimer's ...

Astrocytes as a novel target in Alzheimer's disease

October 11, 2012
Alzheimer's disease is a severe neurodegenerative disease that affects 45% of people over 85 years of age. The research teams of Prof. Jin-Moo Lee at Washington University in Saint Louis, USA, and Prof. Milos Pekny at Sahlgrenska ...

Modified stem cells offer potential pathway to treat Alzheimer's disease

April 15, 2014
UC Irvine neurobiologists have found that genetically modified neural stem cells show positive results when transplanted into the brains of mice with the symptoms and pathology of Alzheimer's disease. The pre-clinical trial ...

Role of calcium in familial Alzheimer's disease clarified, pointing to new therapeutics

May 13, 2014
In 2008 researchers at the Perelman School of Medicine at the University of Pennsylvania showed that mutations in two proteins associated with familial Alzheimer's disease (FAD) disrupt the flow of calcium ions within neurons. ...

Recommended for you

BACE-Inhibitor successfully tested in Alzheimer's animal model

July 28, 2017
The protein amyloid beta is believed to be the major cause of Alzheimer's disease. Substances that reduce the production of amyloid beta, such as BACE inhibitors, are therefore promising candidates for new drug treatments. ...

Scientists use new data mining strategy to spot those at high Alzheimer's risk

July 28, 2017
The push to develop treatments for Alzheimer's disease has been a promising and disappointing endeavor over the past two decades, yielding a greater understanding of the disease yet still failing to generate successful new ...

Lifestyle changes to stave off Alzheimer's? Hints, no proof

July 20, 2017
There are no proven ways to stave off Alzheimer's, but a new report raises the prospect that avoiding nine key risks starting in childhood just might delay or even prevent about a third of dementia cases around the world.

Blood test identifies key Alzheimer's marker

July 19, 2017
A new study led by researchers at Washington University School of Medicine in St. Louis suggests that measures of amyloid beta in the blood have the potential to help identify people with altered levels of amyloid in their ...

Steering an enzyme's 'scissors' shows potential for stopping Alzheimer's disease

July 19, 2017
The old real estate adage about "location, location, location" might also apply to the biochemical genesis of Alzheimer's disease, according to new research from the University of British Columbia.

Brain scans may change care for some people with memory loss

July 19, 2017
Does it really take an expensive brain scan to diagnose Alzheimer's? Not everybody needs one but new research suggests that for a surprising number of patients whose memory problems are hard to pin down, PET scans may lead ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.